Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: A multicentre randomized placebo-controlled trial

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 3, 1999, Pages 277-282

  Ewe, Klaus ^e   Böttger, Thomas ^a   Buhr, Heinz J ^c   Ecker, Karl Wilhelm ^c   Otto, Herwart F ^c   Ueberschaer, B ^c   Gabbert, H E ^b   Vogt, M ^c   Lindemann, W ^c   Remberger, K ^c   Greinwald, R ^c   Tauschel, H D ^c   Gierend, M ^d   Wiegel, D ^d   Weber, A ^d  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c Dr Falk Pharma GmbH ^*

^d Medicomp GmbH   (Germany)

^e NONE   (Germany)

Author keywords

Budesonide; Crohn's disease; Postoperative recurrence

Indexed keywords

BUDESONIDE;

ADULT; ANASTOMOSIS; ARTICLE; CLINICAL TRIAL; COLON RESECTION; COLONOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CUSHING SYNDROME; DEPRESSION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HUMAN; HUMAN TISSUE; ILEUM RESECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; ROSACEA; SIDE EFFECT; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

EID: 0033033651     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199903000-00011     Document Type: Article

References (29)

1. Ewe K, Herfarth Ch, Malchow H, Jesdinski JH. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion 1989; 42:224-232.
2. Fazio VW, Marchetti F, Church M, Goldblum JR, Lavery C, Hull TL, et al. Effect of resection margins on the recurrence of Crohn's disease in the small bowel. A randomized trial. Ann Surg 1996; 224:563-571.
3. Pennington L, Hamilton SR, Bayless TM, Cameron JL. Surgical management of Crohn's disease. Influence of disease at margin of resection. Ann Surg 1980; 192:311-318.
4. Messori A, Brignola R, Trallori G, Rampazzo R, Bardazzi G, Belloli C, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 1994; 89:692- 699.
5. Brignola C, Cottone M, Pera A, Ardizzone S, Scribano ML, de Franchis R, et al., and the Italian Cooperative Study Group. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Gastroenterology 1995; 108:345-349.
6. Caprilli R, Andreoli A, Capurso L, Corrao G, d'Albasio G, Gioieni A, et al., and the Gruppo Italiano per lo Studio del Colon e del Retto. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of postoperative recurrence of Crohn's disease. Aliment Pharmacol Ther 1994; 8:35-43.
7. Fiasse R, Fontaine F, Vanheuverzwyn R. Prevention of Crohn's disease recurrence after intestinal resection with Eudragit-L-coated 5-aminosalicylic acid. Preliminary results of a 1 year double-blind placebo controlled study. Gastroenterology 1991; 100:A208.
8. Florent C, Cortot A, Quandale P, Sahmoud T, Modigliani R, Sarfaty E, et al., and the Group d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Placebo-controlled clinical trial of mesalazine in the prevention of early recurrence after resection for Crohn's disease. Eur J Gastroenterol Hepatol 1996; 8:229-233.
9. McLeod RS, Wolff BG, Steinhart HLH, Carryer PW, O'Rourke K, Andrews DF, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995; 109:404-413.
10. Wenckert A, Kristensen M, Ecklund AE, Barany F, Jarnum S, Waming H, et al. The long-term prophylactic effect of salazosulfapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double-blind trial. Scand J Gastroenterol 1978; 13:161-167.
11. Rutgeerts P, Hiele M, Geboes K, Peeters M, Pennickx F, Aerts R, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108:1617-1621.
12. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86:249-266.
13. Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F Jr, Singleton JW. National cooperative Crohn's disease study: results of drug treatment. Gastroenterology 1979; 77:848-869.
14. Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn's disease at the colonic anastomosis after curative surgery. Gut 1984; 25:665-672.
15. Best WR, Becktel HM, Singleton JW. Rederived values for eight coefficients of the Crohn's disease activity index (CDAI). Gastroenterology 1979; 77:843-846.
16. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hicle M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99:956-963.
17. Lockhardt-Mummery HE, Morson BC. Crohn's disease (regional enteritis) of the large intestine. Gut 1960; 1:87-105.
18. Kelly JK, Sutherland LR. The chronological sequence in the pathology of Crohn's disease. J Clin Gastroenterol 1988; 10:28-33.
19. Haggiff RC. The differential diagnosis of idiopathic inflammatory bowel disease. In: Pathology of colon, small intestine and anus. 2nd edn. Norris HT (editor). New York: Churchill Livingstone; 1991. pp. 23-60.
20. Ridell RH. Pathology of idiopathic inflammatory bowel disease. In: Gastrointestinal pathology and its clinical implications. Lewin KJ, Ridell RH, Weinstein WM (editors). New York: Ikaku-Shoin; 1992. pp. 834-959.
21. Löfberg R, Rutgeerts P, Malchow H, Lamers C, Danielsson A, Olaison G, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo-controlled 1 year study. Gut 1996; 39:82-86.
22. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, Williams CN, et al., and the Canadian Inflammatory Bowel Disease Study Group. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled dose-ranging study. Gastroenterology 1996; 110:45-51.
23. Gross V, Andus T, Ecker KW, Raedler A, Loeschke K, Plauth M, et al. Low dose oral pH-modified release budesonide for maintenance of steroid induced remission in Crohn's disease. Gut 1998; 42:493-496.
24. Hellers G, Löfberg R, Rutgeerts P, Malchow H, Prantera C, Jewell DP, et al. Oral budesonide for prevention of recurrence following ileocaecal resection of Crohn's disease. A one-year placebo-controlled study. Gastroenterology 1996; 110:A923.
25. Möllmann HW, Hochhaus G, Tromm A, Froehlich P, Möllmann AC, Krieg M, et al. Pharmacokinetics and pharmacodynamics of budesonide-pH-modified release capsules.In: Glucocorticoid therapy in chronic inflammatory bowel disease - from basic principles to rational therapy. Möllmann HW, May B (editors). Dordrecht: Kluwer; 1996. pp. 107-120.
26. Edsbäcker S, Wollmer P, Nilsson A, Nilson M. Pharmacokinetics and gastrointestinal transit of budesonide controlled ileal release (CIR) capsules. Gastroenterology 1993; 104:A695.
27. Gabbert HE, Ewe K, Singe CC, Junginger T, Gerharz CD, Köther K. Frührezidive des M. Crohn nach 'Kurativer' lleumresektion. Eine prospektive endoskopische und histologische Untersuchung. Dtsch Med Wochenschr 1990; 115:447-451.
28. D'Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997; 112:1475-1482.
29. Sachar DB. Budesonide for inflammatory bowel disease - is it a magic bullet? N Engl J Med 1994; 331:873-874.